

**Press release**  
**27 February 2019**

## **Ulrik Harrysson appointed new CEO of SyntheticMR AB.**

**The board of directors of SyntheticMR AB has appointed Ulrik Harrysson as new CEO of SyntheticMR AB. He will assume the post latest September 1<sup>st</sup>, 2019.**

Ulrik Harrysson holds a Master's degree in Economics, major in Marketing, from the International Business School in Jönköping. He joins SyntheticMR from a role as Senior Vice President Global Marketing and Sales at Hermes Medical Solutions AB. Hermes develops, markets and sells systems and software for image processing within nuclear medicine. Earlier in his 25-year career, he has held leading international positions in global companies such as HemoCue, Danaher and Pfizer.

Ulrik Harrysson, "I am very enthusiastic about my new role at SyntheticMR. The company has a unique technology that is effectively implemented in innovative and attractive solutions to meet customer needs. The company possesses great expertise in commercializing, marketing and successfully selling these innovations in the market through collaborations and partnerships. I look forward to working with all competent and knowledgeable employees and continue to develop the company and strengthen the position of SyntheticMR in the global market."

For additional information, please contact Staffan Persson, chairman of the board, SyntheticMR AB, +46 70 321 00 98.

**SyntheticMR AB** develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI® delivering multiple, adjustable contrast images and quantitative data from a single 5-6-minute scan – generating increased patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit [www.syntheticmr.com](http://www.syntheticmr.com).

*This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on February 27 2019*